Form 8-K - Current report:
SEC Accession No. 0000950170-23-001839
Filing Date
2023-02-06
Accepted
2023-02-06 08:16:35
Documents
12
Period of Report
2023-02-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20230206.htm   iXBRL 8-K 57215
  Complete submission text file 0000950170-23-001839.txt   179366

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20230206_pre.xml EX-101.PRE 11412
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20230206.xsd EX-101.SCH 2443
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20230206_lab.xml EX-101.LAB 13887
6 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20230206_htm.xml XML 4893
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 23588446
SIC: 2834 Pharmaceutical Preparations